Abstract
We thank David Mark for his comments (1) about our study (2) in which subjects with type 2 diabetes, who were given 1,000 μg chromium in the form of chromium picolinate (CrPic) in combination with 5 mg glipizide, were compared with subjects receiving glipizide plus placebo. Mark suggests that the attenuation in weight gain reported in our study may be indicative of a drug-supplement interaction and suggests that all of the reported differences in body weight gain at the end of the study were caused by an acute weight loss, which occurred within the 1st week after CrPic was started. He …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
